Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ado-Trastuzumab Emtansine in HER2 Amplified or Mutant Cancers
NCT02675829Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2016
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine in solid tumor, lung cancer, bladder cancer, urinary tract cancer, colorectal cancer (CRC), sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2016; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
solid tumorlung cancerbladder cancerurinary tract cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02675829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675829.